机构：[1]Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610051, P.R China四川省人民医院四川省肿瘤医院[2]Department of Clinical Laboratory, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610051, P.R China四川省人民医院四川省肿瘤医院[3]Department of Biostatistics, The University of Texas Health Science Center at Houston, Houston, TX, USA[4]McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA[5]Department of Biochemistry and Molecular Biology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610051, P.R. China四川省人民医院四川省肿瘤医院
The aim of this study was to analyze the prevalence and prognostic value of myeloid differentiation factor 88 (MYD88) L265P in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). We assessed the MYD88 L265P mutation using an allele-specific semi-nested polymerase chain reaction method in 53 DLBCL patients treated with R-CHOP. The MYD88 L265P mutation was detected in 16 of 53 DLBCL (30.19%) samples from patients treated with R-CHOP. Age and location were statistically significantly associated with MYD88 L265P (P=0.025, 0.033, respectively), while treatment response and tumor recurrence were not. Univariate analysis showed that B symptoms (P=0.004) and Ki-67 (P=0.03) were significantly associated with progression-free survival (PFS), while MYD88 L265P showed no significant association with overall survival and PFS. Multivariate analysis showed that B symptoms were significantly associated with PFS. Our study suggests that the prognostic value of MYD88 L265P in DLBCL patients with R-CHOP requires further research.
基金：
Department of Medical Oncology of Sichuan Cancer Hospital and Institute
第一作者机构：[1]Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610051, P.R China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610051, P.R China[5]Department of Biochemistry and Molecular Biology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610051, P.R. China[*1]Department of Biochemistry and Molecular Biology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 55 Section 4, South People's Road, Chengdu, Sichuan 610051, P.R. China[*2]Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Section 4, 55 South People's Road, Chengdu, Sichuan 610051, P.R. China
推荐引用方式(GB/T 7714)：
Yu Sisi,Luo Huaichao,Pan Meiling,et al.High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment[J].ONCOLOGY LETTERS.2018,15(2):1707-1715.doi:10.3892/ol.2017.7472.
APA：
Yu, Sisi,Luo, Huaichao,Pan, Meiling,Palomino, Luis Angel,Song, Xiaoyu...&Zhang, Zhihui.(2018).High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment.ONCOLOGY LETTERS,15,(2)
MLA：
Yu, Sisi,et al."High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment".ONCOLOGY LETTERS 15..2(2018):1707-1715
